# Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients

Study · id `cardio:ct-nct02933788` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02933788](<https://clinicaltrials.gov/study/NCT02933788>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02933788

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 116 participants.

## Technical summary

Registry record NCT02933788. Randomized; no masking; primary purpose prevention. Start 2016-10 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 116 participants (planned count; ClinicalTrials.gov record NCT02933788, source copy `cardio:ctgov-nct02933788-2016-10-14`, retrieved 2026-10-26)
- Start date: 2016-10 (registry gives no type) (ClinicalTrials.gov record NCT02933788, source copy `cardio:ctgov-nct02933788-2016-10-14`, retrieved 2026-10-26)
- Primary completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT02933788, source copy `cardio:ctgov-nct02933788-2016-10-14`, retrieved 2026-10-26)
- Completion: 2018-12 (anticipated) (ClinicalTrials.gov record NCT02933788, source copy `cardio:ctgov-nct02933788-2016-10-14`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02933788-2016-10-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Cilostazol
- Intervention (Drug): Acetylsalicylic acid
- Lead sponsor: Kangbuk Samsung Hospital
- Lead sponsor class: OTHER
- Collaborator: Asan Medical Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Kangbuk Samsung Hospital (`cardio:org-kangbuk-samsung-hospital`)
- Registry lists this organization as a collaborator: Asan Medical Center (`cardio:org-asan-medical-center`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease (`cardio:pubmed-35381686`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2d293340af9a211dc1f5aa3d97d57a7b042b1b61719fde4cfd7e5c6774a63d4d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
